Age-Related Macular Degeneration

SEATTLE — Receiving travel support may help patients with age-related macular degeneration undergo more injections, regardless of the distance needed to travel for treatment, according to research presented at the Association for Research in Vision and Ophthalmology meeting.

The FDA approved Yesafili and Opuviz as the first interchangeable biosimilars to Eylea, according to a press release from the FDA.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher S. Dhoot, MD, discusses 52-week phase 1 data for Axpaxli for the treatment of neovascular age-related macular degeneration.

Intravitreal pegcetacoplan was associated with delayed atrophy of retinal pigment epithelium and photoreceptors among patients with geographic atrophy secondary to age-related macular degeneration, according to research.

SEATTLE — In this Healio Video Perspective from the Retina World Congress, Andrew A. Moshfeghi, MD, MBA, discusses treating patients with age-related macular degeneration with concomitant geographic atrophy and choroidal neovascularization.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses highlights in age-related macular degeneration from the ARVO meeting.

The FDA granted de novo marketing authorization to Notal Vision for the patient self-operated AI-powered Scanly Home OCT device, according to a press release.

SEATTLE — Patients with age-related macular degeneration in a veteran population experienced an increase in inactive disease after treatment with faricimab, according to a poster presented here.

The past 2 years have brought a decisive leap forward in the management of age-related macular degeneration.

SEATTLE — Funding from the Chronic Disease Foundation impacts the decision to stay on a chosen therapy in patients with age-related macular degeneration, according to a poster presentation.